WASF3 and breast cancer: Our pilot study clearly demonstrated that significantly high levels of WAVE3 can easily be detected in the blood collected from BC patients who also developed metastatic disease, compared to the healthy controls, therefore, demonstrating the proof of principle that increased WAVE3 expression levels can be used as a biomarker for the presence of CTCs in the blood of BC patients.